EGFR-TKIs治疗晚期非小细胞肺癌效果的Meta分析

EGFR-TKIs治疗晚期非小细胞肺癌效果的Meta分析

康倩,余正

中国药科大学南京 211198,中国药科大学南京 211198

收稿日期:2013-05-07 修回日期:2013-05-07 出版日期:2013-06-25 发布日期:2013-06-24

Meta-Analysis on EGFR-TKIs in the Treatment of Non-Small Cell Lung Cancer

康倩 and 余正

China Pharmaceutical University,Nanjing,211198,YU Zheng

Received:2013-05-07 Revised:2013-05-07 Online:2013-06-25 Published:2013-06-24

摘要/Abstract

摘要： 目的：根据临床研究文献，采用 Meta 分析法综合评价EGFR-TKIs类药物治疗晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的临床疗效。方法：检索 CNKI、维普、万方、SCI、Pubmed、Science Direct等数据库中2005年至2013 年期间发表的有关EGFR-TKIs对比治疗晚期NSCLC的临床研究资料，采用 RevMan5.0和ITC软件，对入选的国内外10篇有关EGFR-TKIs对比治疗晚期NSCLC的研究文献进行综合定量分析。结果：Meta 分析结果显示，埃克替尼与吉非替尼治疗晚期NSCLC有效率和疾病控制率的RR值分别为1.07(P＝0.69)、1.01(P＝0.89)；吉非替尼与厄洛替尼治疗晚期NSCLC有效率和疾病控制率的RR值分别为1.23(P＝0.10)、1.04(P＝0.46)；埃克替尼与厄洛替尼治疗晚期NSCLC有效率和疾病控制率的RR值分别为1.32(P＝0.79)、1.05(P＝0.95)。结论：埃克替尼、吉非替尼和厄洛替尼治疗晚期NSCLC的效果无显著性差异，但三者的临床有效性尚需要更多高质量的临床随机对照研究来证实。

Abstract: Objective: To conduct a meta-analysis on the clinical trails of EGFR-TKIs for non-small cell lung cancer(NSCLC) and to evaluate its clinical efficacy.Methods: The related literature concerning the clinical trials of EGFR-TKIs in the treatment of NSCLC published both in the domestic and overseas from 2005 to 2013 were retrieved. Meta analysis on the selected literature was conducted by means of Review Manager 5.0 and ITC software. Results: A total of 10 clinical trials were included in our study. The RR value of overall response rate and disease control rate between Icotinib and Gefitinib in patients with NSCLC were 1.07(P＝0.69)、1.01(P＝0.89), respectively. The RR value of overall response rate and disease control rate between Gefitinib and Erlotinib in patients with NSCLC were 1.23(P＝0.10) and 1.04(P＝0.46), respectively. The RR value of overall response rate and disease control rate between Icotinib and Erlotinib in patients with NSCLC were 1.32(P＝0.79) and 1.05(P＝0.95), respectively. Conclusion: It showed no profound significant differences in efficacy between Icotinib and Gefitinib , Gefitinib and Erlotinib, Icotinib and Erlotinib in patients with NSCLC. However, the results should be interpreted with caution because of the quantity and sample size of the included trials. More high quality studies are needed to further prove the results.

康倩,余正. EGFR-TKIs治疗晚期非小细胞肺癌效果的Meta分析[J]. .

康倩 and 余正. Meta-Analysis on EGFR-TKIs in the Treatment of Non-Small Cell Lung Cancer[J]. .

参考文献

[1] AZZOLI CG,BAKER S JR,TEMIN S,et al．American society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non-small -cell lung cancer[J]．J Clin Oncol,2009,27( 36) : 6251 - 6266．
[2] ETTINGER DS,AKERLEY W,BEPLER G,et al． Non-small cell lung cancer[J]．J Natl Compr Canc Netw,2010,8 ( 7) :740 - 801．
[3] Malcolm Ranson, Lisa A. Hammond, David Ferry,et al ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial. Journal of Clinical Oncology, Vol 20, Issue 9(May),2002:2240-2250.
[4] Kris MG, Natale RB, Herbst RS,et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149-2158.
[5] 谭芬来,王印祥等. EGFR-TKIs 治疗非小细胞肺癌进展[J]. Chinese Journal of New Drugs , 2011,20( 17):1594-1601.
[6] Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy[J]. Lung Cancer,2012,75:82-88.
[7] Junshik Hong, Sun Young Kyung, Sang Pyo Lee, et al. Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer[J]. ORIGINAL ARTICLE, 2010,25(3)：294-300.
[8] 王治华,唐勇等. 吉非替尼与厄洛替尼治疗晚期非小细胞肺癌的临床分析[J].实用肿瘤杂志,2010,25(2)：195-199.
[9] 汪海岩,张德芳等. 吉非替尼与厄洛替尼二线治疗晚期非小细胞肺癌的对比研究[J].实用医学杂志,2012,28(20)：3444-3446.
[10] 张晓庆,李玉平等. 吉非替尼与厄洛替尼治疗非小细胞肺癌疗效及药物经济学评价[J].中国新药与临床杂志,2009,28(11)：837-840.
[11] 彭亮. 厄洛替尼与吉非替尼治疗晚期非小细胞肺癌的疗效和生存因素分析[D].北京：军医进修学院解放军总医院,2010.
[12] 张静,刘素勤,张洁等. 晚期非小细胞肺癌二线治疗不同方案的疗效及成本效益分析[J].临床肿瘤学杂志,2012,17(10)：908-911.
[13] 陈建华,罗永忠,王伟等. 盐酸埃克替尼与吉非替尼治疗化疗失败的非小细胞肺癌28 例[J]. Chinese Journal of New Drugs,2012,21( 17)：2056-2059.
[14]陈建华,罗永忠,王伟等. 盐酸埃克替尼治疗晚期非小细胞肺癌III期临床试验[J]. 肿瘤药学,2011,1(5):441-443.
[15] SUN Y,SHI Y,ZHANG L,et al． A randomized,double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer( nsclc) previously treated with chemotherapy( icogen) [J]．J Clin Oncol,2011,29( Suppl) : abstr 7522．
[16]Wells GA, Sultan SA, Chen L, Khan M, Coyle D.Indirect treatment comparison [computer program]. Version 1.0. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
[17]THATCHER N,CHANG A,PARIKH P,et al． Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised,placebo-controlled,multicenter study ( iressa survival evaluation in lung cancer) [J]． Lancet,2005,366( 9496) : 1527 - 1537．